Clinical Trial Update: Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of dasatinib (Sprycel) in hormone-refractory prostate cancer completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Hormone-refractory Prostate Cancer
• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: University of California, Irvine | Conditions: Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Status: COMPLETED | Results posted: 2018-05-25